CNS-derived microparticles: a hypothesis for biomarker-based assessment of neurological complications in β-thalassemia
Issued Date
2025-11-01
Resource Type
ISSN
03069877
eISSN
15322777
Scopus ID
2-s2.0-105017096321
Journal Title
Medical Hypotheses
Volume
204
Rights Holder(s)
SCOPUS
Bibliographic Citation
Medical Hypotheses Vol.204 (2025)
Suggested Citation
Noulsri E., Lerdwana S. CNS-derived microparticles: a hypothesis for biomarker-based assessment of neurological complications in β-thalassemia. Medical Hypotheses Vol.204 (2025). doi:10.1016/j.mehy.2025.111767 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112400
Title
CNS-derived microparticles: a hypothesis for biomarker-based assessment of neurological complications in β-thalassemia
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
β-thalassemia, a prevalent hereditary hematological condition, is associated with multi-organ impairment, including well-documented neurological complications. These neurological sequelae are primarily attributed to chronic anemia and iron overload-induced neurotoxicity. While existing diagnostic methods assess neurological deficits, a more practical and sensitive strategy is critically needed for early detection and effective treatment monitoring in β-thalassemia patients. A comprehensive review of the literature provides compelling evidence that 1) diverse cell types within the central nervous system (CNS) release specific microparticles (MPs); 2) the concentrations of these MPs in biological fluids are directly influenced by pathological damage to their originating cells; and 3) the unique pathological state of β-thalassemia e.g., oxidative stress, hypoxia, inflammation actively contributes to this MP release. Therefore, we hypothesize that elevated concentrations of CNS-derived MPs in β-thalassemia patients will directly correlate with the severity of neurological abnormalities and CNS injury. If rigorously validated through further in vivo and clinical studies, our proposed MP-based assessment could represent a novel and practical approach for determining the early stages of neurological involvement and effectively monitoring CNS recovery following therapy in β-thalassemia.